Anebulo Pharmaceuticals, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation DE
Business Address C/O ANEBULO PHARMACEUTICALS, INC., LAKEWAY, TX, 78734
Mailing Address C/O ANEBULO PHARMACEUTICALS, INC., LAKEWAY, TX, 78734
Phone 737 203 5270
Fiscal Year End 0630
EIN 851170950
Financial Overview
FY2025
$12.15M
Total Assets
$488K
Total Liabilities
$11.63M
Cash & Equivalents
$-0.25
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | February 13, 2026 | View on SEC |
| 10-Q Quarterly financial report | February 12, 2026 | View on SEC |
| 8-K Current report of material events | February 12, 2026 | View on SEC |
| 8-K Current report of material events | February 6, 2026 | View on SEC |
| 8-K Current report of material events | January 29, 2026 | View on SEC |
| 8-K Current report of material events | January 27, 2026 | View on SEC |
| 8-K Current report of material events | December 22, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 13, 2025 | View on SEC |
| 8-K Current report of material events | November 13, 2025 | View on SEC |
| 8-K Current report of material events | September 29, 2025 | View on SEC |
Annual Reports
10-K September 29, 2025
- FDA Fast Track status granted for drug development
- Positive early trial results showing efficacy over placebo
Material Events
8-K Strategy Change February 6, 2026
High Impact
- Significant cost savings from reduced compliance, legal, and accounting expenses.
- Reduced administrative burden associated with public company reporting and Nasdaq listing standards.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.